Coherus Says IP Covering Mega-Drug Humira Is 'Obvious'
Coherus BioSciences Inc. pushed for the invalidation of a patent central to AbbVie Inc.'s mega-blockbuster autoimmune disease drug Humira during an America Invents Act review Thursday, telling a Patent Trial and...To view the full article, register now.
Already a subscriber? Click here to view full article